{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:24:16Z","timestamp":1775096656017,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12977-018-0446-x","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T15:23:20Z","timestamp":1537457000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Potent suppression of HIV-1 cell attachment by Kudzu root extract"],"prefix":"10.1186","volume":"15","author":[{"given":"S.","family":"Mediouni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Jablonski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kessing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Even","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Tellinghuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. T.","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"446_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023\u201335.","journal-title":"N Engl J Med"},{"key":"446_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMra1004180","volume":"365","author":"MA Wainberg","year":"2011","unstructured":"Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365:637\u201346.","journal-title":"N Engl J Med"},{"key":"446_CR3","doi-asserted-by":"publisher","first-page":"9187","DOI":"10.1128\/JVI.75.19.9187-9200.2001","volume":"75","author":"AC Saphire","year":"2001","unstructured":"Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA. Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol. 2001;75:9187\u2013200.","journal-title":"J Virol"},{"key":"446_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/ni1566","volume":"9","author":"J Arthos","year":"2008","unstructured":"Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301\u20139.","journal-title":"Nat Immunol"},{"key":"446_CR5","doi-asserted-by":"publisher","first-page":"20877","DOI":"10.1073\/pnas.0911796106","volume":"106","author":"C Cicala","year":"2009","unstructured":"Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S, Macleod K, O\u2019Shea A, Patel N, Van Ryk D, Wei D, Pascuccio M, Yi L, McKinnon L, Izulla P, Kimani J, Kaul R, Fauci AS, Arthos J. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA. 2009;106:20877\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"446_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0092-8674(00)80694-7","volume":"100","author":"TB Geijtenbeek","year":"2000","unstructured":"Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100:587\u201397 (see comments).","journal-title":"Cell"},{"key":"446_CR7","doi-asserted-by":"publisher","first-page":"12865","DOI":"10.1128\/JVI.77.23.12865-12874.2003","volume":"77","author":"S Gummuluru","year":"2003","unstructured":"Gummuluru S, Rogel M, Stamatatos L, Emerman M. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J Virol. 2003;77:12865\u201374.","journal-title":"J Virol"},{"key":"446_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/096876899294751","volume":"16","author":"PR Clapham","year":"1999","unstructured":"Clapham PR, Reeves JD, Simmons G, Dejucq N, Hibbitts S, McKnight A. HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Mol Membr Biol. 1999;16:49\u201355.","journal-title":"Mol Membr Biol"},{"key":"446_CR9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1128\/JVI.74.4.1961-1972.2000","volume":"74","author":"PD Kwong","year":"2000","unstructured":"Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol. 2000;74:1961\u201372.","journal-title":"J Virol"},{"key":"446_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/31359","volume":"393","author":"JP Moore","year":"1998","unstructured":"Moore JP, Binley J. HIV. Envelope\u2019s letters boxed into shape. Nature. 1998;393:630\u20131 (news; comment).","journal-title":"Nature"},{"key":"446_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.tim.2011.02.001","volume":"19","author":"M Caffrey","year":"2011","unstructured":"Caffrey M. HIV envelope: challenges and opportunities for development of entry inhibitors. Trends Microbiol. 2011;19:191\u20137.","journal-title":"Trends Microbiol"},{"key":"446_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/v4020309","volume":"4","author":"CA Didigu","year":"2012","unstructured":"Didigu CA, Doms RW. Novel approaches to inhibit HIV entry. Viruses. 2012;4:309\u201324.","journal-title":"Viruses"},{"key":"446_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1592\/phco.24.2.198.33141","volume":"24","author":"H Hardy","year":"2004","unstructured":"Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:198\u2013211.","journal-title":"Pharmacotherapy"},{"key":"446_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1345\/aph.1D143","volume":"37","author":"ML Duffalo","year":"2003","unstructured":"Duffalo ML, James CW. Enfuvirtide: a novel agent for the treatment of HIV-1 infection. Ann Pharmacother. 2003;37:1448\u201356.","journal-title":"Ann Pharmacother"},{"key":"446_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72:e1\u201325.","journal-title":"Drugs"},{"key":"446_CR16","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","volume":"49","author":"P Dorr","year":"2005","unstructured":"Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"446_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1592\/phco.29.3.295","volume":"29","author":"JS Hunt","year":"2009","unstructured":"Hunt JS, Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy. 2009;29:295\u2013304.","journal-title":"Pharmacotherapy"},{"key":"446_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.antiviral.2011.09.010","volume":"92","author":"WJ Fessel","year":"2011","unstructured":"Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, Petropoulos CJ, Shafer RW. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment. Antiviral Res. 2011;92:484\u20137.","journal-title":"Antiviral Res"},{"key":"446_CR19","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1111\/j.1750-3841.2012.02887.x","volume":"77","author":"Y Zhong","year":"2012","unstructured":"Zhong Y, Li Y, Zhao Y. Physicochemical, microstructural, and antibacterial properties of beta-chitosan and kudzu starch composite films. J Food Sci. 2012;77:E280\u20136.","journal-title":"J Food Sci"},{"key":"446_CR20","first-page":"3156","volume":"35","author":"G Li","year":"2010","unstructured":"Li G, Zhang Q, Wang Y. Chemical constituents from roots of Pueraria lobata. Zhongguo Zhong Yao Za Zhi. 2010;35:3156\u201360.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"446_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.drugalcdep.2015.05.025","volume":"153","author":"DM Penetar","year":"2015","unstructured":"Penetar DM, Toto LH, Lee DY, Lukas SE. A single dose of kudzu extract reduces alcohol consumption in a binge drinking paradigm. Drug Alcohol Depend. 2015;153:194\u2013200.","journal-title":"Drug Alcohol Depend"},{"key":"446_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1021\/np5009416","volume":"78","author":"B Liu","year":"2015","unstructured":"Liu B, Kongstad KT, Qinglei S, Nyberg NT, Jager AK, Staerk D. Dual high-resolution alpha-glucosidase and radical scavenging profiling combined with HPLC-HRMS-SPE-NMR for identification of minor and major constituents directly from the crude extract of Pueraria lobata. J Nat Prod. 2015;78:294\u2013300.","journal-title":"J Nat Prod"},{"key":"446_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.chroma.2009.12.017","volume":"1217","author":"G Du","year":"2010","unstructured":"Du G, Zhao HY, Zhang QW, Li GH, Yang FQ, Wang Y, Li YC, Wang YT. A rapid method for simultaneous determination of 14 phenolic compounds in Radix puerariae using microwave-assisted extraction and ultra high performance liquid chromatography coupled with diode array detection and time-of-flight mass spectrometry. J Chromatogr A. 2010;1217:705\u201314.","journal-title":"J Chromatogr A"},{"key":"446_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/ptr.5083","volume":"28","author":"YX Zhou","year":"2014","unstructured":"Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res. 2014;28:961\u201375.","journal-title":"Phytother Res"},{"key":"446_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jcph.96","volume":"53","author":"Z Zhang","year":"2013","unstructured":"Zhang Z, Lam TN, Zuo Z. Radix puerariae: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2013;53:787\u2013811.","journal-title":"J Clin Pharmacol"},{"key":"446_CR26","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.1128\/JVI.00302-14","volume":"88","author":"ME Abram","year":"2014","unstructured":"Abram ME, Ferris AL, Das K, Quinones O, Shao W, Tuske S, Alvord WG, Arnold E, Hughes SH. Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication. J Virol. 2014;88:7589\u2013601.","journal-title":"J Virol"},{"key":"446_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-3155-8-1","volume":"8","author":"HH Lara","year":"2010","unstructured":"Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology. 2010;8:1.","journal-title":"J Nanobiotechnology"},{"key":"446_CR28","doi-asserted-by":"publisher","first-page":"14410","DOI":"10.1073\/pnas.222366699","volume":"99","author":"J Ren","year":"2002","unstructured":"Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci USA. 2002;99:14410\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"446_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350400900115","volume":"9","author":"M Witvrouw","year":"2004","unstructured":"Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57\u201365.","journal-title":"Antivir Ther"},{"key":"446_CR30","first-page":"139","volume":"7","author":"E Poveda","year":"2005","unstructured":"Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 2005;7:139\u201347.","journal-title":"AIDS Rev"},{"key":"446_CR31","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1128\/JVI.64.10.5177-5182.1990","volume":"64","author":"TF Schulz","year":"1990","unstructured":"Schulz TF, Whitby D, Hoad JG, Corrah T, Whittle H, Weiss RA. Biological and molecular variability of human immunodeficiency virus type 2 isolates from the Gambia. J Virol. 1990;64:5177\u201382.","journal-title":"J Virol"},{"key":"446_CR32","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.3390\/md13063454","volume":"13","author":"Y Sato","year":"2015","unstructured":"Sato Y, Morimoto K, Kubo T, Sakaguchi T, Nishizono A, Hirayama M, Hori K. Entry inhibition of influenza viruses with high mannose binding lectin ESA-2 from the red alga Eucheuma serra through the recognition of viral hemagglutinin. Mar Drugs. 2015;13:3454\u201365.","journal-title":"Mar Drugs"},{"key":"446_CR33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.celrep.2016.12.068","volume":"18","author":"K Rausch","year":"2017","unstructured":"Rausch K, Hackett BA, Weinbren NL, Reeder SM, Sadovsky Y, Hunter CA, Schultz DC, Coyne CB, Cherry S. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against zika virus. Cell Rep. 2017;18:804\u201315.","journal-title":"Cell Rep"},{"issue":"18","key":"446_CR34","doi-asserted-by":"publisher","first-page":"e00847","DOI":"10.1128\/JVI.00847-17","volume":"91","author":"CH Fellinger","year":"2017","unstructured":"Fellinger CH, Gardner MR, Bailey CC, Farzan M. Simian immunodeficiency virus SIVmac239, but not SIVmac316, binds and utilizes Human CD4 more efficiently than rhesus CD4. J Virol. 2017;91(18):e00847.","journal-title":"J Virol"},{"key":"446_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1084\/jem.20101907","volume":"208","author":"CR Ruprecht","year":"2011","unstructured":"Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Gunthard HF, Rusert P, Trkola A. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med. 2011;208:439\u201354.","journal-title":"J Exp Med"},{"key":"446_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1742-4690-8-45","volume":"8","author":"A Rapista","year":"2011","unstructured":"Rapista A, Ding J, Benito B, Lo YT, Neiditch MB, Lu W, Chang TL. Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment. Retrovirology. 2011;8:45.","journal-title":"Retrovirology"},{"key":"446_CR37","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1093\/emboj\/18.23.6771","volume":"18","author":"AC Saphire","year":"1999","unstructured":"Saphire AC, Bobardt MD, Gallay PA. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO J. 1999;18:6771\u201385.","journal-title":"EMBO J"},{"key":"446_CR38","doi-asserted-by":"publisher","first-page":"21353","DOI":"10.1074\/jbc.M500911200","volume":"280","author":"RR Vives","year":"2005","unstructured":"Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem. 2005;280:21353\u20137.","journal-title":"J Biol Chem"},{"issue":"1","key":"446_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2012.05.016","volume":"12","author":"G Mousseau","year":"2012","unstructured":"Mousseau G, Clementz MA, Bakeman WN, Nagarsheth N, Cameron M, Shi J, Baran P, Fromentin R, Chomont N, Valente ST. An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription. Cell Host Microbe. 2012;12(1):97\u2013108.","journal-title":"Cell Host Microbe."},{"key":"446_CR40","doi-asserted-by":"publisher","first-page":"9.19.1","DOI":"10.1002\/0471141755.ph0919s72","volume":"72","author":"RJ Tallarida","year":"2016","unstructured":"Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Protoc Pharmacol. 2016;72:9.19.1\u201319.19.","journal-title":"Curr Protoc Pharmacol"},{"key":"446_CR41","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1128\/JVI.00168-09","volume":"83","author":"C Pan","year":"2009","unstructured":"Pan C, Cai L, Lu H, Qi Z, Jiang S. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains. J Virol. 2009;83:7862\u201372.","journal-title":"J Virol"},{"key":"446_CR42","doi-asserted-by":"publisher","first-page":"e00465","DOI":"10.1128\/mBio.00465-15","volume":"6","author":"G Mousseau","year":"2015","unstructured":"Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST. The tat inhibitor didehydro-Cortistatin A prevents HIV-1 reactivation from latency. MBio. 2015;6:e00465.","journal-title":"MBio"},{"key":"446_CR43","doi-asserted-by":"publisher","first-page":"11979","DOI":"10.1074\/jbc.M210914200","volume":"278","author":"SS Carroll","year":"2003","unstructured":"Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M, Olsen DB. Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs. J Biol Chem. 2003;278:11979\u201384.","journal-title":"J Biol Chem"},{"key":"446_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science. 2005;309:623\u20136.","journal-title":"Science"},{"key":"446_CR45","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1128\/AAC.02574-15","volume":"60","author":"S Thenin-Houssier","year":"2016","unstructured":"Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, Opp S, Buffone C, Fuhrmann J, Kota S, Billack B, Pietka-Ottlik M, Tellinghuisen T, Choe H, Spicer T, Scampavia L, Diaz-Griffero F, Kojetin DJ, Valente ST. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrob Agents Chemother. 2016;60:2195\u2013208.","journal-title":"Antimicrob Agents Chemother"},{"key":"446_CR46","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1128\/JVI.77.10.5678-5684.2003","volume":"77","author":"JM Binley","year":"2003","unstructured":"Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol. 2003;77:5678\u201384.","journal-title":"J Virol"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-018-0446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12977-018-0446-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-018-0446-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T04:15:14Z","timestamp":1662092114000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-018-0446-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1186\/s12977-018-0446-x","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"1 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"64"}}